Leonard S. Schleifer net worth and biography

Leonard Schleifer Biography and Net Worth

Leonard S. Schleifer, MD, PhD, founded Regeneron in 1988, has been a Director and the company’s President and Chief Executive Officer since its inception. He served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Dr. Yancopoulos, has grown Regeneron from a tiny startup into a ~$50 billion market cap company, with a unique science-driven culture, successful drug discovery and development engine and seven FDA-approved medicines. Dr. Schleifer has been recognized as one of Barron’s Best CEOs and as an Ernst & Young Entrepreneur of the Year. He graduated from Cornell University and earned his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician, certified in Neurology by the American Board of Psychiatry and Neurology, and worked as a practicing neurologist before founding Regeneron.

What is Leonard S. Schleifer's net worth?: The estimated net worth of Leonard S. Schleifer is at least $39.39 million as of June 11th, 2024. Dr. Schleifer owns 55,134 shares of Regeneron Pharmaceuticals stock worth more than $39,391,589 as of December 26th. This net worth approximation does not reflect any other investments that Dr. Schleifer may own. Additionally, Dr. Schleifer receives a salary of $8,180,000.00 as CEO at Regeneron Pharmaceuticals. Learn More about Leonard S. Schleifer's net worth.
How old is Leonard S. Schleifer?: Dr. Schleifer is currently 71 years old. There are 5 older executives and no younger executives at Regeneron Pharmaceuticals. Learn More on Leonard S. Schleifer's age.
What is Leonard S. Schleifer's salary?: As the CEO of Regeneron Pharmaceuticals, Inc., Dr. Schleifer earns $8,180,000.00 per year. Learn More on Leonard S. Schleifer's salary.
How do I contact Leonard S. Schleifer?: The corporate mailing address for Dr. Schleifer and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Leonard S. Schleifer's contact information.
Has Leonard S. Schleifer been buying or selling shares of Regeneron Pharmaceuticals?: Leonard S. Schleifer has not been actively trading shares of Regeneron Pharmaceuticals during the past quarter. Most recently, Leonard S. Schleifer sold 9,064 shares of the business's stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a transaction totalling $9,203,857.52. Following the completion of the sale, the chief executive officer now directly owns 55,134 shares of the company's stock, valued at $55,984,717.62. Learn More on Leonard S. Schleifer's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 106,315 shares worth more than $104,138,555.84. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Leonard S. Schleifer Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/11/2024	Sell	9,064	$1,015.43	$9,203,857.52	55,134
6/6/2024	Sell	787	$1,015.02	$798,820.74	64,198
5/17/2024	Sell	22,830	$979.23	$22,355,820.90	466,877
5/14/2024	Sell	25,000	$979.25	$24,481,250.00	408,200
4/5/2022	Sell	4,461	$710.05	$3,167,533.05	465,922
3/31/2022	Sell	2,886	$710.01	$2,049,088.86	465,922
8/18/2021	Sell	200,000	$650.03	$130,006,000.00
5/12/2020	Sell	150,922	$569.22	$85,907,820.84	599,499
1/2/2015	Sell	1,500	$410.58	$615,870.00
11/12/2014	Sell	45,817	$400.30	$18,340,545.10
10/28/2014	Sell	69,112	$404.01	$27,921,939.12
9/9/2013	Sell	5,000	$275.47	$1,377,350.00

Leonard S. Schleifer Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $714.47

$706.15

$720.00

50 Day Range

MA: $803.10

$701.85

$998.23

2 Week Range

Now: $714.47

$693.00

$1,211.20

Volume

382,145 shs

Average Volume

568,805 shs

Market Capitalization

$78.51 billion

P/E Ratio

17.68

Dividend Yield

N/A

Beta

0.08

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

Leonard Schleifer Biography and Net Worth

What is Leonard S. Schleifer's net worth?

How old is Leonard S. Schleifer?

What is Leonard S. Schleifer's salary?

How do I contact Leonard S. Schleifer?

Has Leonard S. Schleifer been buying or selling shares of Regeneron Pharmaceuticals?

Who are Regeneron Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Regeneron Pharmaceuticals?